A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior Chemotherapy
- First Posted Date
- 2025-04-17
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 390
- Registration Number
- NCT06931717
- Locations
- 🇦🇹
Wien AKH, Wien, Austria
🇫🇷CHU d'Angers, Angers, France
🇩🇪Ruhrlandklinik Essen, Essen, Germany
A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 290
- Registration Number
- NCT06284317
- Locations
- 🇦🇺
Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia
🇦🇺Nepean Hospital, Penrith, New South Wales, Australia
🇦🇺Royal North Shore Hospital, St Leonards, New South Wales, Australia
AMG510 (sotorasib) Plus Lenvatinib As Second-line Treatment in Patients with KRASG12C Mutant, Metastatic NSCLC
- Conditions
- Metastatic Non Small Cell Lung CancerKRAS G12C
- Interventions
- First Posted Date
- 2023-10-05
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Registration Number
- NCT06068153
- Locations
- 🇪🇸
Hospital Universitario Y Politécnico La Fe, Valencia, Spain
🇦🇹Medical University of Innsbruck / UK für Innere Medizin V, Innsbruck, Austria
🇨ðŸ‡Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland
A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2023-06-09
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 220
- Registration Number
- NCT05896566
- Locations
- 🇫🇷
Gustave Roussy Cancer Center, Villejuif, France
🇩🇪HELIOS Klinikum Berlin Buch, Berlin, Germany
🇩🇪Praxisklinik Krebsheilkunde formerly MediOnko-Institut GbR, Berlin, Germany
Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC
- First Posted Date
- 2023-02-08
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 44
- Registration Number
- NCT05718323
- Locations
- 🇫🇷
CHU - Angers, Angers, France
🇫🇷Centre Hospitalier d'Avignon, Avignon, France
🇫🇷Caen - CHU, Caen, France
Brigatinib Post Definitive Chemo-radiotherapy in Patients with ALK-fusion Non-small Cell Lung Cancer
- Conditions
- ALK-rearrangementNSCLC, Stage III
- Interventions
- First Posted Date
- 2023-02-08
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 44
- Registration Number
- NCT05718297
- Locations
- 🇫🇷
CHU Angers, Angers, France
🇫🇷Caen - CHU, Caen, France
🇫🇷Hôpital de Marseille, Marseille, France
Adagrasib in Patients With KRASG12C-mutant NSCLC Who Are Elderly or Have Poor Performance Status
- First Posted Date
- 2023-01-06
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 68
- Registration Number
- NCT05673187
- Locations
- 🇮🇪
St James's Hospital, Dublin, Ireland
🇮🇪University Hospital Limerick, Limerick, Ireland
🇧🇪Instiute Jules Bordet, Brussels, Belgium
Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2022-11-01
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 60
- Registration Number
- NCT05601973
- Locations
- 🇮🇹
SS Antonio e Biagio e Cesare Arrigo Hospital, Alessandria, Italy
🇫🇷Chu Angers, Angers, France
🇫🇷Centre Hospitalier d'Avignon, Avignon, France
Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer
- Conditions
- Non-Small Cell Lung CancerMelanoma
- Interventions
- Radiation: Stereotactic radiosurgeryDrug: Immune checkpoint inhibitor
- First Posted Date
- 2022-08-31
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 190
- Registration Number
- NCT05522660
- Locations
- 🇮🇹
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Napoli, Italy
🇮🇹Santa Maria della Misericordia Hospital, Perugia, Italy
🇮🇹Istituto Nazionale Tumori "Regina Elena", Roma, Italy
Osimertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR Mutant NSCLC (STEREO)
- Conditions
- NSCLC Stage IVEGFR Gene Mutation
- Interventions
- Radiation: Stereotactic Body Radiation Therapy (SBRT)
- First Posted Date
- 2021-06-01
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 6
- Registration Number
- NCT04908956
- Locations
- 🇰🇷
National Cancer Center, Goyang-si, Korea, Republic of
🇰🇷Severance Hospital, Yonsei University Health System, Sinchon-dong, Korea, Republic of
🇪🇸Hospital General de Alicante, Alicante, Spain